Boehringer's phase 3 schizophrenia program misses primary goal
Fecha de publicación:
16/01/2025
Fuente: FierceBiotech
Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a trio of late-stage trials.